ES3057657T3 - Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases - Google Patents

Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases

Info

Publication number
ES3057657T3
ES3057657T3 ES19791401T ES19791401T ES3057657T3 ES 3057657 T3 ES3057657 T3 ES 3057657T3 ES 19791401 T ES19791401 T ES 19791401T ES 19791401 T ES19791401 T ES 19791401T ES 3057657 T3 ES3057657 T3 ES 3057657T3
Authority
ES
Spain
Prior art keywords
compound
alport
subject
approximately
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19791401T
Other languages
English (en)
Spanish (es)
Inventor
Radko Komers
Celia Jenkinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Travere Therapeutics Inc
Original Assignee
Travere Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Travere Therapeutics Inc filed Critical Travere Therapeutics Inc
Application granted granted Critical
Publication of ES3057657T3 publication Critical patent/ES3057657T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ES19791401T 2018-10-04 2019-10-03 Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases Active ES3057657T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862741270P 2018-10-04 2018-10-04
US201962853904P 2019-05-29 2019-05-29
US201962894559P 2019-08-30 2019-08-30
PCT/US2019/054559 WO2020072814A1 (en) 2018-10-04 2019-10-03 Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases

Publications (1)

Publication Number Publication Date
ES3057657T3 true ES3057657T3 (en) 2026-03-03

Family

ID=68318947

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19791401T Active ES3057657T3 (en) 2018-10-04 2019-10-03 Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases

Country Status (13)

Country Link
US (1) US11207299B2 (https=)
EP (1) EP3860594B1 (https=)
JP (2) JP7524167B2 (https=)
KR (1) KR102902972B1 (https=)
CN (1) CN113286587A (https=)
AU (1) AU2019354784B2 (https=)
BR (1) BR112021006132A2 (https=)
CA (1) CA3114434A1 (https=)
ES (1) ES3057657T3 (https=)
IL (1) IL281965B1 (https=)
MA (1) MA53817A (https=)
MX (1) MX2021003606A (https=)
WO (1) WO2020072814A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117017985A (zh) 2016-10-13 2023-11-10 特拉维尔治疗公司 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
WO2022246200A1 (en) * 2021-05-21 2022-11-24 Travere Therapeutics, Inc. Methods of treating kidney diseases or disorders
WO2022266370A1 (en) * 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan for treating idiopathic pulmonary fibrosis
JP2025183466A (ja) * 2022-11-11 2025-12-17 株式会社アークメディスン 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
HUP0104634A3 (en) 1998-07-06 2002-11-28 Bristol Myers Squibb Co Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
ATE339417T1 (de) 1999-12-15 2006-10-15 Bristol Myers Squibb Co Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten
WO2010114801A1 (en) 2009-03-31 2010-10-07 Ligand Pharmaceuticals Inc. Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
WO2010135350A2 (en) 2009-05-20 2010-11-25 Pharmacopeia, Llc Biphenyl intermediate compounds and methods for the preparation of a dual angiotensin ii and endothelin a receptor antagonist
US9719981B2 (en) 2012-08-17 2017-08-01 Father Flanagan's Boys' Home RAC1 inhibitors for the treatment of alport glomerular disease
CA2958585C (en) * 2014-08-21 2024-01-09 Stealth Biotherapeutics Corp Use of peptide d-arg-2',6'-dmt-lys-phe-nh2 for the treatment of alport syndrome
EP3515501A1 (en) * 2016-09-19 2019-07-31 Aten Porus Lifesciences Cyclodextrin based polymers, methods, compositions and applications thereof
CN117017985A (zh) * 2016-10-13 2023-11-10 特拉维尔治疗公司 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
US20220048900A1 (en) 2018-12-21 2022-02-17 Travere Therapuetics, Inc. Amorphous sparsentan compositions

Also Published As

Publication number Publication date
JP7524167B2 (ja) 2024-07-29
MX2021003606A (es) 2021-08-16
BR112021006132A2 (pt) 2021-07-20
US20200147050A1 (en) 2020-05-14
JP2024133735A (ja) 2024-10-02
MA53817A (fr) 2021-08-11
CN113286587A (zh) 2021-08-20
EP3860594B1 (en) 2025-10-01
CA3114434A1 (en) 2020-04-09
AU2019354784A1 (en) 2021-04-15
IL281965A (en) 2021-05-31
WO2020072814A1 (en) 2020-04-09
JP2022514152A (ja) 2022-02-10
AU2019354784B2 (en) 2025-07-10
IL281965B1 (en) 2026-04-01
US11207299B2 (en) 2021-12-28
KR20210081338A (ko) 2021-07-01
KR102902972B1 (ko) 2025-12-22
EP3860594A1 (en) 2021-08-11

Similar Documents

Publication Publication Date Title
ES3057657T3 (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases
ES2386786T3 (es) Método para tratar rubor cutáneo usando agonistas selectivos de receptores alpha-2-adrenérgicos.
ES2618907T3 (es) Composiciones farmacéuticas en crema que comprenden oximetazolina
KR102528435B1 (ko) 신장 질환 또는 장애의 치료를 위한 비페닐 설폰아미드 화합물
ES2638070T3 (es) Procedimiento para tratar afecciones neurológicas con glucósidos cardiacos
ES2675316T3 (es) Dosificación farmacéutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil-)-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina para el tratamiento del dolor neuropático
ES2935605T3 (es) Combinaciones de cannabinoides y N-aciletanolaminas
JP5212849B2 (ja) 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
JP2025087858A (ja) トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
US12042505B2 (en) Compositions and methods for treating dry eye
WO2022246200A1 (en) Methods of treating kidney diseases or disorders
US20240325324A1 (en) Compositions and methods for treating dry eye
HK40059411B (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases
HK40059411A (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases
AU2024343419A1 (en) Sparsentan for treating immunoglobulin a nephropathy (igan)
KR20260021653A (ko) IgA 매개 질환의 치료 방법에 사용하기 위한 스파르센탄
WO2024073672A1 (en) Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
CA3071096A1 (en) Co-administration of minocycline and colistin to reduce acute kidney injury
BR122025008185A2 (pt) Usos terapêuticos de compostos de bifenil sulfonamida para a fabricação de um medicamento para tratar doenças ou transtornos renais em um indivíduo